United States Agency for International Development (USAID) Ghana Acting Mission Director, Janean Davis, announced $24.7 million in new funding to Ghana today to support vaccination efforts nationwide as part of the Initiative for Global Vaccine Access (Global VAX). 

The funding provided through USAID will accelerate the delivery of safe and effective COVID-19 vaccinations in every part of Ghana. 

Director General of the Ghana Health Service, Dr Patrick Kuma-Aboagye and other Ghana Health Service officials joined USAID Ghana Acting Mission Director Janean Davis at the Greater Accra Regional (Ridge) Hospital to make the announcement.  

“The bottom line is that vaccines are safe, effective, and readily available in Ghana. We realize, however, that the donation of vaccines is not enough.

“That’s why, today, I am excited to announce on behalf of the U.S. government an additional $24.7 million to Ghana to accelerate the delivery of safe and effective Covid-19 vaccinations as part of Global VAX,” said Acting USAID Ghana Mission Director Janean Davis.

Acting Mission Director Janean Davis also announced the recent arrival of nearly two million more Pfizer Covid-19 vaccines, which arrived in Ghana on March 21.

Since September 2021, the United States has donated more than 9.6 million Covid-19 vaccines to Ghana, representing more than 30 per cent of all vaccines available in Ghana.

Worldwide, the United States has donated more than 500 million vaccine doses, including 144 million doses, to 43 countries in Sub-Saharan Africa.

Global VAX is a U.S. Government effort to contribute to the worldwide goal to vaccinate 70% of the population of every country against Covid-19 in 2022.

It is a whole-of-government approach that builds on President Biden’s extraordinary commitment to donate more than 1.2 billion vaccine doses by the end of 2022 and intensifies efforts to get shots in arms.

Global VAX encompasses the U.S. Government’s work with more than 100 countries in every region of the world to increase the uptake of Covid-19 vaccines.

It will also incorporate an intensive surge of financial, technical, and diplomatic engagement in an initial group of countries with both significant need and potential for rapid progress, with an initial focus on sub-Saharan Africa.